AI-generated · cited to primary sources · not investment advice
Eli Lilly and Company Common Stock (LLY) Dec 2025 Filing Analysis
What could break the thesis?
Pricing pressure is stable but significant. U.S. realized prices dropped by 10% in 2025, primarily driven by Mounjaro and Zepbound rebates. (1 stable)
“In the U.S., the volume increase and the lower realized prices in 2025 were primarily driven by Mounjaro and Zepbound... Price (10)% [in the U.S.].”
The risk is stable as litigation continues. A U.S. District Court ruled against Lilly's cash replenishment model in May 2025, which the company is now appealing. (1 stable)
“The U.S. District Court for the District of Columbia agreed with HRSA in May 2025 that the government must preapprove Lilly’s cash replenishment model, which HRSA has not done. Lilly appealed that decision to the U.S. Court of Appeals.”
See the full cited Risk analysis of Eli Lilly and Company Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.